PMC

Individual patient results for normalized whole body clearance (A) and hepatic clearance (B) of ¹¹¹In-ch806 at the 5 mg/m² (■), 10 mg/m² (▵), 20 mg/m² (▿), and 40 mg/m² (⧫) dose levels. Linear regression for data sets is indicated in each image [r² = 0.9595 (A); r² = 0.9415 (B)].

Biodistribution and tumor localization of ¹¹¹In-ch806. (A and B) Whole body gamma camera images of patient 7, anterior (A) and posterior (B), on day 5 after infusion of ¹¹¹In-ch806. High uptake of ¹¹¹In-ch806 in metastatic lesions in the lungs (arrows) is evident. (C and D) Metastatic lesions (arrows) on scan. (E) 3D SPECT images of the chest. (F) Coregistered transaxial images of SPECT and CT showing specific uptake of ¹¹¹In-ch806 in metastatic lesions.

ch806 targeting of glioma. (A–C) Planar images of the head and neck of patient 8 obtained on day 0 (A), day 3 (B), and day 7 (C) after infusion of ¹¹¹In-ch806. Initial blood pool activity is seen on day 0, and uptake of ¹¹¹In-ch806 in an anaplastic astrocytoma in the right frontal lobe is evident by day 3 (arrow) and increases by day 7. (D–F) Specific uptake of ¹¹¹In-ch806 is confirmed in SPECT image of the brain (D) (arrow), at the site of tumor (arrow) evident in ¹⁸F-FDG (FDG, Fluorodeoxyglucose) positron emission tomography (E), and MRI (F).